Long
VVUS hits a bottom. Breaking out of falling wedge formation
- Qysmia looks to be gaining from new online marketing efforts
- Endo will start promoting Vivus' ED drug
- 36% short interest!
- Institutional investors adding at these levels
- Recently hit a 10-year-low, but things have never looked brighter for VVUS
PT: $10
Timeframe: 18 - 24 months (possibly sooner, depending on how ED drug sales are)
Disclosure: Long $2 Jan 2017 calls @1.10/contract
- Endo will start promoting Vivus' ED drug
- 36% short interest!
- Institutional investors adding at these levels
- Recently hit a 10-year-low, but things have never looked brighter for VVUS
PT: $10
Timeframe: 18 - 24 months (possibly sooner, depending on how ED drug sales are)
Disclosure: Long $2 Jan 2017 calls @1.10/contract
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.